SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates2/15/2005 5:10:54 AM
   of 631
 
Low dose methotrexate vasculoprotective in psoriasis patients.

NEW YORK Mon Feb 14 (Reuters Health) - Methotrexate, used for the treatment of rheumatoid arthritis and psoriasis, may also reduce the risk of atherosclerosis and circulatory diseases affecting the heart and brain, investigators have found.

As Dr. Robert S. Kirsner told Reuters Health, "the finding that treatment of psoriasis -- and rheumatoid arthritis -- reduced the risk of development of vascular disease...suggests that patients with these diseases may derive benefit from treatment beyond control of their skin and joint disease."

Kirsner, at the University of Miami, and colleagues note in the American Academy of Dermatology that methotrexate is an analog of folate and has anti-inflammatory effects that may help reduce vascular disease. However, it may also promote higher levels of a compound called homocysteine, which can increase the risk of vascular disease.

To see how these two factors balance out in reality, the researchers studied data on 7615 outpatients with psoriasis and 6707 with rheumatoid arthritis who were treated at Veterans Administration facilities in Florida or Puerto Rico.

Those with psoriasis who were prescribed methotrexate had a significantly reduced risk of vascular disease compared with those who were not. The risk was lowest -- at 50 percent -- in those given a low dose of methotrexate. Similar but less pronounced risk reductions were seen in arthritis patients.

Despite its tendency to adversely affect homocysteine levels, methotrexate therapy "may provide further vasculoprotective benefits." the researchers conclude.

SOURCE: American Academy of Dermatology, February 2005.

By David Douglas
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News